Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNMD Mind Medicine (MindMed) Inc.

Trading 04-23 11:16:48 EDT

6.22

+0.42

+7.24%

High6.33	Low6.00	Vol429.78K
Open6.02	D1 Closing5.80	Amplitude5.78%
Mkt Cap468.79M	Tradable Cap436.80M	Total Shares75.37M
T/O2.66M	T/O Rate0.61%	Tradable Shares70.22M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MNMD","market":"US","secType":"STK","nameCN":"Mind Medicine (MindMed) Inc.","latestPrice":6.22,"timestamp":1745421399975,"preClose":5.8,"halted":0,"volume":429780,"delay":0,"floatShares":70224604,"shares":75368359,"eps":-1.542397,"marketStatus":"Trading","change":0.42,"latestTime":"04-23 11:16:48 EDT","open":6.02,"high":6.33,"low":5.995,"amount":2664399.1912200004,"amplitude":0.057759,"askPrice":6.22,"askSize":300,"bidPrice":6.21,"bidSize":96,"shortable":3,"etf":0,"ttmEps":-1.542397,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745438400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":5.8,"preHourTrading":{"tag":"盘前","latestPrice":5.89,"preClose":5.8,"latestTime":"09:28 EDT","volume":9637,"amount":57499.6645151,"timestamp":1745414903168},"postHourTrading":{"tag":"盘后","latestPrice":5.95,"preClose":5.8,"latestTime":"19:58 EDT","volume":52588,"amount":310396.85,"timestamp":1745366289830},"volumeRatio":1.951052,"impliedVol":0.8825,"impliedVolPercentile":0.5},"requestUrl":"/m/hq/s/MNMD/wiki","defaultTab":"wiki","newsList":[{"id":"2529683112","title":"Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529683112","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529683112?lang=en_us&edition=full_marsco","pubTime":"2025-04-23 20:37","pubTimestamp":1745411850,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Mind Medicine  implies that they have significant influence over the company's share price. Ownership research along with  analyst forecasts data  help provide a good understanding of opportunities in a stock. Every investor in Mind Medicine  Inc.  should be aware of the most powerful shareholder groups. With 50% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential .We can see that Mind Medicine  does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Mind Medicine , . Of course, keep in mind that there are other fact","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/institutional-investors-own-significant-stake-123730402.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USJW.SI","BK4585","IE00B3QW5Z07.USD","QID","PSQ","NVIW.SI","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","BK4007","BK4547","QLD","LU2210149790.SGD","NQmain","MNMD","IE00BGHQF748.EUR","IE00BKPKM429.USD",".IXIC","TSYW.SI","BK4588","MNQmain","TQQQ","USAW.SI","BK4112","LU2095319765.USD","SQQQ"],"gpt_icon":1},{"id":"2529358356","title":"BRIEF-Mind Medicine (Mindmed) Inc - Mindmed Enters Into First Amendment To Loan And Security Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529358356","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529358356?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 04:29","pubTimestamp":1745267360,"startTime":"0","endTime":"0","summary":"BRIEF-Mind Medicine  Inc - Mindmed Enters Into First Amendment To Loan And Security Agreement - SEC FilingApril 21  - Mind Medicine  Inc MNMD.O:MIND MEDICINE  INC - MINDMED ENTERS INTO FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT - SEC FILINGMIND MEDICINE  INC - AMENDED CREDIT AGREEMENT PROVIDES TERM LOANS UP TO $120 MILLION - SEC FILINGSource text: [ID:n0001104659-25-036841]Further company coverage: MNMD.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ0W9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD","BK4547","BK4007"],"gpt_icon":0},{"id":"2529243330","title":"Mind Medicine (MindMed) Inc - MindMed Enters Into First Amendment to Loan and Security Agreement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2529243330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529243330?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 04:20","pubTimestamp":1745266855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ0W9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNMD","BK4547","BK4007"],"gpt_icon":0},{"id":"2527344698","title":"Mind Medicine Doses First Patient in Phase 3 Trial on MM120 for Major Depressive Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2527344698","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527344698?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 22:48","pubTimestamp":1744728539,"startTime":"0","endTime":"0","summary":"Mind Medicine  said Tuesday that it dosed the first patient in the phase 3 study evaluating MM120 orally disintegrating tablet or ODT, for the treatment of major depressive disorder.The study will evaluate 100 microgram doses of the drug candidate for efficacy and safety compared with placebo in about 140 participants in the US, according to the company.The company said the trial will consist of a 12-week randomized, double blind, placebo-controlled study followed by a 40-week open-label period. Top-line data from the first part is expected in the second half of 2026.MM120 ODT is a pharmaceutically optimized form of lysergide D-tartrate or LSD, Mind Medicine added.Shares of the company were up 3.2% in recent trading.Price: 5.78, Change: +0.23, Percent Change: +4.14","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0},{"id":"2527549926","title":"BRIEF-Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527549926","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527549926?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:04","pubTimestamp":1744715093,"startTime":"0","endTime":"0","summary":"BRIEF-Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd)April 15 (Reuters) - Mind Medicine (MindMed) Inc MNMD.O:MINDMED ANNOUNCES FIRST PATIENT D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA1NDFNQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4547","MNMD"],"gpt_icon":0},{"id":"2527499665","title":"Mind Medicine (MindMed) Inc - Topline Data Expected in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2527499665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527499665?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:00","pubTimestamp":1744714802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA1NDFNQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MNMD","BK4547"],"gpt_icon":0},{"id":"2527496753","title":"MindMed Announces First Patient Dosed in Phase 3 Emerge Study of Mm120 in Major Depressive Disorder (Mdd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527496753","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527496753?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:00","pubTimestamp":1744714802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nTUA1NDFNQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4547","MNMD","BK4007"],"gpt_icon":0},{"id":"2527541636","title":"MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2527541636","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527541636?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"- Emerge is the first Phase 3 study of lysergide D-tartrate  in MDD; primary endpoint will measure change from baseline in Montgomery-sberg Depression Rating Scale  score at Week 6 between MM120 Orally Disintegrating Tablet  100 g and placebo -. - Topline data from the 12-week double-blind period anticipated in the second half of 2026 -. \"In our Phase 2b study, MADRS score improvements after a single MM120 100 g dose were clinically and statistically significant compared to placebo, providing meaningful benefits to participants. Having dosed the first participant in the Phase 3 Emerge study, we are excited for the therapeutic potential that MM120 ODT shows for the 21 million people in the U.S. affected by MDD,\" said Daniel R. Karlin, M.D., M.A., Chief Medical Officer of MindMed. \"By running our MDD and GAD Phase 3 studies concurrently, we can leverage the shared symptomatology between these conditions to more effectively match participants to the appropriate study based on their clinic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-first-patient-dosed-110000855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4547","ODT","BK4139","ABVC","BK4007","MNMD"],"gpt_icon":0},{"id":"2522008197","title":"MindMed Announces New Employee Inducement Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2522008197","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522008197?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 04:01","pubTimestamp":1742846460,"startTime":"0","endTime":"0","summary":"NEW YORK, March 24, 2025----Mind Medicine  Inc.  , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common shares of the Company , with an effective grant date of March 24, 2025. The Options have an exercise price equal to the closing price of MindMed’s common shares on March 21, 2025, the last trading day on which MindMed’s common shares traded prior to the date of the grant, and will vest over a four-year period with 25% vesting on the first anniversary of the grant and the remaining 75% vesting in substantially equal monthly increments over the three-year period thereafter, subject to each employee’s continued employment.The Options were granted as a material inducement to each employee’s employment and were approved by MindMed's Compensation Committee on March 19, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-announces-employee-inducement-grants-200100745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","USJW.SI","PSQ","QID","SQQQ","BK4007","MNMD","USAW.SI","NQmain","QLD",".IXIC","TQQQ","BK4547","MNQmain","NVIW.SI"],"gpt_icon":1},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGNPF","MNMD","GHRS","CMND","PSYGF","MYCOF","SEEL","MIRA","CYBN","BK4547","RLMD","ALID","FLHLF","NUMIF","QNTM","CMPS","OPTHF","SILO","KTTA","IXHL","BK4202","SPRC","SNPX","ATAI","MDXXF","BK4168","PHRRF","PBM","BK4539","ENTBF","BK4139","NRXP","BETRF","DRUG","BK4007","RVVTF"],"gpt_icon":0},{"id":"2520093546","title":"MindMed Appoints Matt Wiley as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520093546","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520093546?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 19:00","pubTimestamp":1742209203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUA63Z4Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4547","MNMD"],"gpt_icon":0},{"id":"2520541217","title":"MindMed Appoints Matt Wiley as Chief Commercial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520541217","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520541217?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 19:00","pubTimestamp":1742209200,"startTime":"0","endTime":"0","summary":"NEW YORK, March 17, 2025----Mind Medicine  Inc. , , a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer . In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company’s commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet  for generalized anxiety disorder  and major depressive disorder .\"Matt’s deep experience in launching multiple neuroscience and psychiatric therapeutics will be invaluable as we prepare for our first potential FDA approval of MM120 ODT,\" said Rob Barrow, Chief Executive Officer of MindMed. \"His proven track record in driving commercial success for novel, first-in-class products like XYREM will be an asset in realizing the significant commercial potential of MM120. As we approach multiple key clinical readouts from our ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mindmed-appoints-matt-wiley-chief-110000560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2294711713.HKD","LU2357125470.USD","LU2249611893.SGD","USJW.SI",".IXIC","BK4547","LU0823414478.USD","MNQmain","QID","QLD","ODT","TQQQ","BK4009","TSYW.SI","USAW.SI","SQQQ","LU2506951792.HKD","PSQ","NQmain","LU0823414551.USD","CCO","MNMD","BK4007","NVIW.SI"],"gpt_icon":1},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QNTM","PSYGF","ENTBF","SPRC","SEEL","BK4168","RLMD","SILO","KTTA","BK4539","IXHL","BETRF","GHRS","CYBN","BK4547","NRXP","MNMD","CMPS","DRUG","CMND","AGNPF","ENVB","ALID","FLHLF","BK4202","MDXXF","RVVTF","SNPX","MIRA","ATAI","NUMIF","PBM","OPTHF","MYCOF","BK4139","BK4007","PHRRF"],"gpt_icon":0},{"id":"2518798399","title":"Analysts Conflicted on These Healthcare Names: Mind Medicine (MNMD), RAPT Therapeutics (RAPT) and LifeMD (LFMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518798399","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518798399?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 15:40","pubTimestamp":1741678852,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mind Medicine (MNMD – Research Report), RAPT Thera...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-mind-medicine-mnmd-rapt-therapeutics-rapt-and-lifemd-lfmd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-mind-medicine-mnmd-rapt-therapeutics-rapt-and-lifemd-lfmd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNMD","BK4007","BK4547","LFMD","BK4137","RAPT","BK4183","BK4139","BK4167","HCSG"],"gpt_icon":0},{"id":"2518289954","title":"Mind Medicine’s (MNMD) Recent Achievements Boosting Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2518289954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518289954?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 00:56","pubTimestamp":1741452997,"startTime":"0","endTime":"0","summary":"Mind Medicine ($MNMD) announced its Q4 financials and indicated it is making strides in developing innovative treatments for brain health disorders...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/mind-medicines-mnmd-recent-achievements-boosting-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/mind-medicines-mnmd-recent-achievements-boosting-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNMD","BK4547","BK4007"],"gpt_icon":0},{"id":"2517436191","title":"Mind Medicine Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2517436191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517436191?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 22:02","pubTimestamp":1741356120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 09:02 ET (14:02 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2517480020","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mind Medicine (MNMD), SurModics (SRDX) and Enhabit, Inc (EHAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480020","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480020?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:11","pubTimestamp":1741353062,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mind Medicine (MNMD – Research Report), SurModics (SRDX – Researc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-mind-medicine-mnmd-surmodics-srdx-and-enhabit-inc-ehab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-mind-medicine-mnmd-surmodics-srdx-and-enhabit-inc-ehab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","SRDX","BK4547","MNMD","BK4082","BK4196","EHAB","HCSG","BK4007"],"gpt_icon":0},{"id":"2517484554","title":"Mind Medicine Price Target Maintained With a $55.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2517484554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517484554?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:11","pubTimestamp":1741349460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 07:11 ET (12:11 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2517163295","title":"Mind Medicine (MindMed) Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2517163295","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517163295?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 22:32","pubTimestamp":1741271525,"startTime":"0","endTime":"0","summary":"Mind Medicine (MindMed) Inc reports results for the quarter ended December 31 - Earnings SummaryMind Medicine (MindMed) Inc MNMD.OQ reported a quarterly adjusted loss of 41 cents per share for the qua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nL5N3PP1HW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0},{"id":"2517156151","title":"Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156151","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156151?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 20:03","pubTimestamp":1741262632,"startTime":"0","endTime":"0","summary":"Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.30) by 36.67 percent. This is a 30.51 percent increase over losses of $(0.59) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44162318/mind-medicine-q4-2024-gaap-eps-0-41-misses-0-30-estimate-cash-and-cash-equivalents-of-273-7m-as-of-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mind Medicine Q4 2024 GAAP EPS $(0.41) Misses $(0.30) Estimate, Cash And Cash Equivalents Of $273.7M As Of December 31, 2024, Expected To Fund Operations Into 2027 And Extend At Least 12 Months Beyond The First Phase 3 Topline Data Readout For MM120 Orally Disintegrating Tablet In Generalized Anxiety Disorder","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mindmed.co","stockEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":-0.1369},{"period":"3month","weight":-0.172},{"period":"6month","weight":-0.0507},{"period":"1year","weight":-0.3318},{"period":"ytd","weight":-0.1667}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.097954},{"month":2,"riseRate":0.75,"avgChangeRate":0.162614},{"month":3,"riseRate":0.25,"avgChangeRate":0.069329},{"month":4,"riseRate":0.5,"avgChangeRate":-0.017503},{"month":5,"riseRate":0.25,"avgChangeRate":-0.037122},{"month":6,"riseRate":0.5,"avgChangeRate":-0.112493},{"month":7,"riseRate":0.75,"avgChangeRate":0.159384},{"month":8,"riseRate":0.25,"avgChangeRate":-0.108659},{"month":9,"riseRate":0,"avgChangeRate":-0.300494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.039054},{"month":11,"riseRate":0.5,"avgChangeRate":0.060477},{"month":12,"riseRate":0.25,"avgChangeRate":-0.119824}],"exchange":"NASDAQ","name":"Mind Medicine (MindMed) Inc.","nameEN":"Mind Medicine (MindMed) Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mind Medicine (MindMed) Inc.,MNMD,Mind Medicine (MindMed) Inc.股票,Mind Medicine (MindMed) Inc.股票老虎,Mind Medicine (MindMed) Inc.股票老虎国际,Mind Medicine (MindMed) Inc.行情,Mind Medicine (MindMed) Inc.股票行情,Mind Medicine (MindMed) Inc.股价,Mind Medicine (MindMed) Inc.股市,Mind Medicine (MindMed) Inc.股票价格,Mind Medicine (MindMed) Inc.股票交易,Mind Medicine (MindMed) Inc.股票购买,Mind Medicine (MindMed) Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mind Medicine (MindMed) Inc.(MNMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mind Medicine (MindMed) Inc.(MNMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction